1.Pharmaceutical Care for One Patient with Severe Bone Marrow Suppression Complicated with Pulmonary Infection Induced by Albumin Bound Paclitaxel
China Pharmacist 2016;19(7):1325-1327
Objective:To provide reference for clinical pharmacist in the treatment of severe bone marrow suppression complicated with infection induced by chemotherapeutic drugs .Methods:The pharmaceutical care was performed by clinical pharmacist for a pa-tient with severe bone marrow suppression complicated with pulmonary infection caused by chemotherapy .The suggestions on the drug use in the evaluation of chemotherapy regimen and the treatment of bone marrow suppression and infection were provided .Results:The bone marrow inhibition was relieved , the pulmonary infection was improved , and no other severe adverse reactions were shown .Con-clusion:Clinical pharmacist can improve effectiveness and safety in the treatment of patients with severe bone marrow suppression by providing individualized drug treatment .
2.GC-MS analysis of volatile oils from fresh and processed typhonii rhizoma.
Tingting ZHANG ; Xiaozhen CHEN ; Yinggang LUO
China Journal of Chinese Materia Medica 2011;36(10):1337-1341
Typhonii Rhizoma is a toxic traditional Chinese medicine. Its toxic components remained unclear. To compare chemical composition of volatile oils from fresh and processed Typhonii Rhizoma qualitatively, volatile oils were obtained by stream distillation and analyzed by GC-MS. The data obtained from GC-MS were processed by principal component analysis. From the essential oils of fresh and processed Typhonii Rhizoma, 43 compounds and 34 compounds were identified respectively. The chemical composition and content in the two oils was different. In the two essential oils 15 identical components were detected. The chemical components and their contents in the essential oils are changing with the storage.
Araceae
;
chemistry
;
Drugs, Chinese Herbal
;
chemistry
;
Gas Chromatography-Mass Spectrometry
;
methods
;
Oils, Volatile
;
chemistry
3.Clinical study on the risk of sarcopenia in patients with advanced lung cancer undergoing anti-tumor therapy
Xiaozhen LUO ; Lingling XIE ; Xiaozhen LEI ; Lili YANG ; Xin YANG ; Yan LIAO
Chongqing Medicine 2024;53(9):1348-1352
Objective To analyze the influencing factors of sarcopenia in patients with advanced lung cancer undergoing anti-tumor therapy,and to explore the adverse effects of sarcopenia on patients with ad-vanced lung cancer undergoing anti-tumor therapy.Methods Patients with advanced lung cancer who received anti-tumor therapy in the Department of Oncology of a tertiary hospital in Chengdu from January to December 2021 were continuously included.The incidence situation of sarcopenia in patients with advanced lung cancer undergoing anti-tumor therapy was evaluated by using the 12th thoracic spine (T12) skeletal muscle index (SMI) standard.According to the diagnostic criteria of sarcopenia,the patients were divided into the sarcope-nia group and the non-sarcopenia group.Multivariate logistic regression was used to analyze the influencing factors of sarcopenia in patients with advanced lung cancer undergoing anti-tumor therapy.Results A total of 285 patients were included in this study,of which 123 cases (43.15%) were diagnosed as sarcopenia.Multiva-riate analysis showed that gender (P<0.001),pathological stage (P=0.012),creatinine (P=0.031) and BMI (P<0.001) were the influencing factors of sarcopenia in patients with advanced lung cancer undergoing anti-tumor therapy.The quality of life score of patients in the sarcopenia group was significantly lower than that in the non-sarcopenia group (P=0.035).Conclusion The incidence of sarcopenia in patients with ad-vanced lung cancer undergoing anti-tumor therapy is high,which is related to many factors and affects the quality of life.
4.Identification of differentially expressed genes related to blastic crisis in chronic myeloid leukemia.
Xujing LUO ; Jinfang ZHANG ; Xiaoli LIU ; Qingfeng DU ; Na XU ; Lulu XU ; Bintao HUANG ; Xiaozhen XIAO
Journal of Southern Medical University 2012;32(6):840-842
OBJECTIVETo identify differentially expressed genes between chronic phase and blast crisis in chronic myeloid leukemia, explore the mechanism and screen potential biomarkers of disease progression.
METHODSThe differences in the gene expression profiles of bone marrow mononuclear cells between chronic phase and blastic crisis were examined using DNA microarray. PANTHER database, Genomatix database and Bibliosphere software were used to analyze and predict the critical genes or transcription factors during disease progression. Some of the genes or transcription factors were selected for verification by semi-quantitative RT-PCR.
RESULTSIn blastic crisis, 68 of the 1176 tested genes were obviously up-regulated. Sixteen of these differential genes were selectively expressed in leukocyte membranes. CD40, CCR3, LGALS3, RGS3, CEACAM3 and the related transcription factors RAC1, CTNNB1, TP53, and NF-κB, all as the nodes of the entire regulatory network, were presumed to play key roles in disease progression. The results of RT-PCR were consistent with the microarray data and showed high expression of CEACAM3, RGS3, CTNNB1 and RAC1 in blastic crisis.
CONCLUSIONA group of genes have been identified to very likely play key roles or serve as biomarkers in the transition from the chronic phase to blastic crisis in chronic myeloid leukemia.
Blast Crisis ; genetics ; Computational Biology ; Gene Expression Profiling ; Gene Expression Regulation, Leukemic ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; genetics ; Oligonucleotide Array Sequence Analysis ; Transcriptome
5.Enlightenment of innovation and transformation experience of World-class research institutions on scientific and technological innovation in health field
Xue JIANG ; Peixin HE ; Xiaozhen LAI ; Ya TU ; Maoguo LUO ; Yiyi LIU
Chinese Journal of Medical Science Research Management 2021;34(1):41-45
Objective:To study the international situation of technology innovation and transfer, to improve the performance in the health field of China.Methods:Collect data and status quo of innovation and transformation of scientific and technological achievements in 10 World-class research universities and hospitals through literature review, and conduct summary analysis.Results:According to the study, the health field is the main arena of technology innovation and transfer in which the status of the main body of innovation of hospitals cannot be ignored, and the transformation ability of some hospitals is higher than universities.Technology innovation and transfer in the health field is characterized by multiple disciplines, long-term and high cost, and it is necessary to build a full ecological chain from research and development (R&D) to production and commercialization.Conclusions:The dominant position of the health field and hospitals in technology innovation and transfer needs to be emphasized.Interdisciplinary collaboration and innovative economy building should be strengthened.
6.Application of language intervention in the regulation of psychological stress during endoscopic retrograde cholangiopancreatography examination
Xiaoyan LUO ; Xiaozhen CHEN ; Wanhua YANG
Chinese Journal of Modern Nursing 2018;24(12):1437-1440
Objective To investigate the application effect of language intervention in the regulation of psychological stress of patients during endoscopic retrograde cholangiopancreatography (ERCP) examination. Methods A total of 70 ERCP patients in Yiwu Central Hospital from April 2013 to May 2017 were included in the study using simple stratified sampling method. A number of 35 cases from April 2013 to April 2015 were recruited as the control group and received routine health education. Another 35 cases from May 2015 to May 2017 were included in the observation group who received additional language intervention. The heart rate, blood pressure, Self-Rating Anxiety Scale (SAS) score, Self-Rating Depression Scale (SDS) score, blood glucose and cortisol levels of patients at different time points were compared between two groups. Results The time factor and between group factor of heart rate, blood pressure, blood glucose and cortisol levels of patients had interaction effect (P< 0.05). The scores of SAS and SDS in the observation group were lower than the scores before the examination,and the differences were statistically significant (P< 0.05). After the examination, there were statistically significant differences in the SAS and SDS scores between two groups (P< 0.05). Conclusions The application of language intervention during the ERCP examination can significantly improve the psychological stress state of patients and the safety of ERCP.
7.Cytogenetic differences between adults and children with acute lymphoblastic leukemia: eight-probe fluorescence in situ hybridization and karyotype analyses.
Yuan ZUO ; Qingfeng DU ; Rong LI ; Na XU ; Rui CAO ; Libin LIAO ; Lulu XU ; Jinfang ZHANG ; Bintao HUANG ; Xujing LUO ; Xiaozhen XIAO ; Xiaoli LIU
Journal of Southern Medical University 2012;32(5):707-709
OBJECTIVETo investigate the cytogenetic differences between children and adults with acute lymphoblastic leukemia (ALL) using eight-probe fluorescence in situ hybridization and karyotype analysis.
METHODSEight-probe (MYC, P16, E2A, TEL/AML1, BCR/ABL , MLL , IGH, and hyperdiploidy) fluorescence in situ hybridization and karyotype analysis were performed for 86 adults and 39 children with acute lymphoblastic leukemia.
RESULTSEight-probe fluorescence in situ hybridization showed significant differences in the positivity rate of TEL/AML1, BCR/ABL, and hyperdiploidy between adult patients and children with ALL. By karyotype analysis, the positivity rate of t(9;22) and hyperdiploidy differed significantly between the children and adult patients (P<0.05).
CONCLUSIONAdults and children with ALL have different expression profiles of the fusion genes. Eight-probe fluorescence in situ hybridization is time-saving, accurate and efficient in detecting common genetic abnormalities in ALL patients, and can be well complementary to karyotype analysis in clinical diagnosis of ALL.
Adolescent ; Adult ; Child ; Child, Preschool ; Cytogenetics ; Female ; Humans ; In Situ Hybridization, Fluorescence ; methods ; Infant ; Karyotype ; Karyotyping ; Male ; Middle Aged ; Precursor Cell Lymphoblastic Leukemia-Lymphoma ; diagnosis ; genetics ; Young Adult
8.Research progress on ambivalence over emotional expression in patients with breast cancer
Xiaozhen CAO ; Yangqiu BAO ; Jia LUO ; Lingjuan ZENG ; Guo CHEN
Chinese Journal of Nursing 2023;58(21):2598-2603
Reducing the level of emotional expression conflict of patients is of great significance to promote the functional recovery of breast cancer patients,improve their prognosis and improve their quality of life.We introduce the research progress of ambivalence over emotional expression in breast cancer patients in terms of the connotation,measurement tools,influencing factors,and intervention methods.There is still a lack of research on measuring the emotional expression conflict of breast cancer patients in China,and it is still necessary to develop a measurement tool with cultural characteristics to obtain the true level of emotional expression conflict of patients.In clinical practice,complementary and alternative medicine,cognitive behavioral intervention,mindfulness training,expressive writing intervention,and other intervention strategies have achieved certain results in improving patients'negative emotions,but personalized intervention strategies still need further exploration.
9.Long-term hypomethylating agents in patients with myelodysplastic syndromes: a multi-center retrospective study
Xiaozhen LIU ; Shujuan ZHOU ; Jian HUANG ; Caifang ZHAO ; Lingxu JIANG ; Yudi ZHANG ; Chen MEI ; Liya MA ; Xinping ZHOU ; Yanping SHAO ; Gongqiang WU ; Xibin XIAO ; Rongxin YAO ; Xiaohong DU ; Tonglin HU ; Shenxian QIAN ; Yuan LI ; Xuefen YAN ; Li HUANG ; Manling WANG ; Jiaping FU ; Lihong SHOU ; Wenhua JIANG ; Weimei JIN ; Linjie LI ; Jing LE ; Wenji LUO ; Yun ZHANG ; Xiujie ZHOU ; Hao ZHANG ; Xianghua LANG ; Mei ZHOU ; Jie JIN ; Huifang JIANG ; Jin ZHANG ; Guifang OUYANG ; Hongyan TONG
Chinese Journal of Hematology 2024;45(8):738-747
Objective:To evaluate the efficacy and safety of hypomethylating agents (HMA) in patients with myelodysplastic syndromes (MDS) .Methods:A total of 409 MDS patients from 45 hospitals in Zhejiang province who received at least four consecutive cycles of HMA monotherapy as initial therapy were enrolled to evaluate the efficacy and safety of HMA. Mann-Whitney U or Chi-square tests were used to compare the differences in the clinical data. Logistic regression and Cox regression were used to analyze the factors affecting efficacy and survival. Kaplan-Meier was used for survival analysis. Results:Patients received HMA treatment for a median of 6 cycles (range, 4-25 cycles) . The complete remission (CR) rate was 33.98% and the overall response rate (ORR) was 77.02%. Multivariate analysis revealed that complex karyotype ( P=0.02, OR=0.39, 95% CI 0.18-0.84) was an independent favorable factor for CR rate. TP53 mutation ( P=0.02, OR=0.22, 95% CI 0.06-0.77) was a predictive factor for a higher ORR. The median OS for the HMA-treated patients was 25.67 (95% CI 21.14-30.19) months. HMA response ( P=0.036, HR=0.47, 95% CI 0.23-0.95) was an independent favorable prognostic factor, whereas complex karyotype ( P=0.024, HR=2.14, 95% CI 1.10-4.15) , leukemia transformation ( P<0.001, HR=2.839, 95% CI 1.64-4.92) , and TP53 mutation ( P=0.012, HR=2.19, 95% CI 1.19-4.07) were independent adverse prognostic factors. There was no significant difference in efficacy and survival between the reduced and standard doses of HMA. The CR rate and ORR of MDS patients treated with decitabine and azacitidine were not significantly different. The median OS of patients treated with decitabine was longer compared with that of patients treated with azacitidine (29.53 months vs 20.17 months, P=0.007) . The incidence of bone marrow suppression and pneumonia in the decitabine group was higher compared with that in the azacitidine group. Conclusion:Continuous and regular use of appropriate doses of hypomethylating agents may benefit MDS patients to the greatest extent if it is tolerated.